Vax Before Cancer

 → September 19th, 2020

Eliminating fake vaccine news with pharmacist, nurse, and physician review.

Sep 18 • 11:43 am CDT

Roche announced on September 18, 2020, that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma, who have not received prior systemic therapy.

Sep 18 • 10:42 am CDT

Agenus Inc. presented preliminary results on September 18, 2020, from two large clinical trials of more than 150 patients each at the European Society for Medical Oncology Virtual Congress 2020. Both trials were conducted in patients with recurrent/metastatic cervical cancer which has limited effective treatment options and disproportionately affects younger women.

“Balstilimab has shown activity in both PD-L1 positive and negative tumors, suggesting that we may have a potentially differentiated PD-1,” stated Dr. Garo Armen, CEO of Agenus, in a press release. “Furthermore, we have also shown important expansion in response rates, to near doubling in PD-L1 positive patients, and durability of response when patients receive zalifrelimab in combination with balstilimab.”

Sep 18 • 5:52 am CDT

A recent Harris Survey that a major opportunity for physicians and patients to improve communication when discussing treatment options was on what – and how much – information should be shared over the course of treatment planning.

Multiple myeloma patients wanted to know more about their treatment options, as more than half reported a desire to have more information about maintenance therapy that might help influence their decisions, on topics such as the long-term side effects of maintenance therapy and the risk of relapse without maintenance therapy.

However, about half of patients (51%) surveyed reported challenges in identifying which information sources are trustworthy. That said, patients agreed their physician put them at ease (100%) and provided understandable explanations (96%).

Sep 16 • 7:15 pm CDT

The American Cancer Society (ACS) has released updated guidelines for cervical cancer screening. The ACS recommendations include a switch to human papillomavirus (HPV) testing alone every 5 years for women who are aged 25 to 65 years, moving away from recommending cytology-based screening via Pap testing.

Updated HPV vaccine development news is published by Vax-Before-Cancer.

Sep 15 • 3:00 pm CDT

According to a study published in the JAMA on August 31, 2020, prostatectomy rates increased from 22.8% in 2004 to 40.5% in 2016, nearly equaling radiotherapy rates by 2016. The ProtecT trial compared prostatectomy vs radiotherapy and showed no difference in prostate-cancer specific mortality.

These researchers stated: 'Randomized data comparing modalities do not and likely will not exist, in the foreseeable future to determine optimal prostate cancer treatment. Clinical trials are needed to guide optimal care.'

For more articles, try our search.